Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01910-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Yen-Ting Lai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Organophosphates, Piperazines, Anti-HIV Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: amfAR, The Foundation for AIDS Research.
Abstract (Originalsprache)
BMS-818251, a fostemsavir analog, is a next-generation HIV-1 attachment inhibitor with enhanced potency and a similar resistance profile. By using ex vivo viral outgrowth assays with HIV+ donor samples, we demonstrate here that BMS-818251 exhibits superior viral suppression compared to temsavir, the active form of fostemsavir. To map potential resistance pathways, we employed deep mutational scanning and pseudotyped virus neutralization assays to identify escape mutations within the HIV-1 envelope glycoprotein (Env). These mutations were largely clustered around the BMS-818251 binding site, with key resistance mutations reducing drug-binding affinity. Several of the enriched mutations, such as S375I/N, M426L, and M475I, have been previously observed in fostemsavir-treated patients, highlighting their clinical relevance. Isothermal titration calorimetry revealed reduced binding affinity as the primary mechanism of resistance, though with notable exceptions, such as R429G, suggesting additional factors to influence viral escape. Ex vivo Env sequencing confirmed selection of resistance mutations under BMS-818251 pressure, reinforcing the predictive value of deep mutational scanning for in vivo resistance monitoring. Compared to fostemsavir, BMS-818251 achieved more effective viral suppression at lower concentrations, even in donor samples harboring preexisting resistance mutations. These findings support the continued development of BMS-818251 as a promising alternative to fostemsavir, with potential benefits for patients with multidrug-resistant HIV-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- N-MER Therapeutics, Boston, Massachusetts, USA.
- Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
- Howard Hughes Medical Institute, Seattle, Washington, USA.
- Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, Cambridge, Massachusetts, USA.
ORCID-Profile: Yen-Ting Lai, Jesse D Bloom, Peter D Kwong
Förderung
- amfAR, The Foundation for AIDS Research
Zitieren
APA
Lai, Y. T., Dingens, A. S., DeMouth, M., Helmold Hait, S., O'Dell, S., Schon, A., Olia, A. S., Wang, T., Shrader, H. R., Lovelace, S. E., Pegu, A., Doria-Rose, N. A., Mascola, J. R., Bloom, J. D., & Kwong, P. D. (2025). Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01910-24
Vancouver
Lai YT, Dingens AS, DeMouth M, Helmold Hait S, O'Dell S, Schon A, et al. Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01910-24
BibTeX
@article{Lai2025,
author = {Lai, Yen-Ting and Dingens, Adam S and DeMouth, Megan and Helmold Hait, Sabrina and O'Dell, Sijy and Schon, Arne and Olia, Adam S and Wang, Tao and Shrader, Hannah R and Lovelace, Sarah E and Pegu, Amarendra and Doria-Rose, Nicole A and Mascola, John R and Bloom, Jesse D and Kwong, Peter D},
title = {Fostemsavir analog BMS-818251 has enhanced viral neutralization potency and similar escape mutation profile},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01910-24}
}
EUVIMED